Susquehanna International Group
VRDN icon

Susquehanna International Group’s Viridian Therapeutics VRDN Stock Holding History

Susquehanna International Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Buy
130,284
+76,007
+140% +$1.22M ﹤0.01% 6079
2026
Q1 		$1.06M Sell
54,277
-62,247
-53% -$1.85M ﹤0.01% 7737
2025
Q4 		$3.63M Buy
116,524
+78,884
+210% +$2.16M ﹤0.01% 4554
2025
Q3 		$812K Sell
37,640
-88,383
-70% -$1.59M ﹤0.01% 7833
2025
Q2 		$1.76M Buy
126,023
+16,039
+15% +$218K ﹤0.01% 6072
2025
Q1 		$1.48M Buy
109,984
+14,119
+15% +$240K ﹤0.01% 6243
2024
Q4 		$1.84M Buy
95,865
+19,956
+26% +$434K ﹤0.01% 5509
2024
Q3 		$1.73M Buy
75,909
+26,698
+54% +$436K ﹤0.01% 5575
2024
Q2 		$640K Sell
49,211
-5,229
-10% -$72.4K ﹤0.01% 7659
2024
Q1 		$953K Buy
54,440
+29,122
+115% +$565K ﹤0.01% 7033
2023
Q4 		$551K Sell
25,318
-6,329
-20% -$99.9K ﹤0.01% 8415
2023
Q3 		$485K Sell
31,647
-178,349
-85% -$3.4M ﹤0.01% 8296
2023
Q2 		$5M Buy
209,996
+117,670
+127% +$3.02M ﹤0.01% 3546
2023
Q1 		$2.35M Buy
92,326
+76,822
+495% +$2.46M ﹤0.01% 4804
2022
Q4 		$453K Sell
15,504
-8,782
-36% -$202K ﹤0.01% 8126
2022
Q3 		$498K Sell
24,286
-62,968
-72% -$1.13M ﹤0.01% 8502
2022
Q2 		$1.01M Sell
87,254
-10,273
-11% -$138K ﹤0.01% 6516
2022
Q1 		$1.8M Buy
+97,527
New +$1.87M ﹤0.01% 5710
2020
Q2 		– Sell
-3,014
Closed -$20K – 11007
2020
Q1 		$20K Buy
+3,014
New +$35.1K ﹤0.01% 9939
2019
Q3 		– Sell
-747
Closed -$23K – 10910
2019
Q2 		$23K Buy
+747
New +$30K ﹤0.01% 9993
2017
Q2 		– Sell
-946
Closed -$177K – 9897
2017
Q1 		$177K Buy
+946
New +$163K ﹤0.01% 8103
2016
Q3 		– Sell
-120
Closed -$11K – 9118
2016
Q2 		$11K Buy
+120
New +$14.7K ﹤0.01% 8420
2015
Q2 		– Sell
-69
Closed -$34K – 10502
2015
Q1 		$34K Buy
+69
New +$39.9K ﹤0.01% 9211

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Susquehanna International Group's VRDN Position: Q2 2026 in Review

Susquehanna International Group increased its Viridian Therapeutics (VRDN) stake by 140% in Q2 2026, buying an estimated $1.22M and bringing the position to 130,284 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #6079.

Susquehanna International Group first reported a position in VRDN in Q1 2015 and has held it in 23 quarters since. The position peaked at $5M in Q2 2023. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Susquehanna International Group held 130,284 shares of Viridian Therapeutics worth $2.39M as of Q2 2026.
  • Susquehanna International Group bought 76,007 Viridian Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Viridian Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #6079 holding.
  • Susquehanna International Group first reported a position in Viridian Therapeutics in Q1 2015 and has held it in 23 quarters since.
  • Susquehanna International Group's Viridian Therapeutics position peaked at $5M in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.